Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Bylvay™ (odevixibat) – New orphan drug approval
July 20, 2021 - Albireo Pharma announced the FDA approval of Bylvay (odevixibat), for the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC).
